Puretech Health Stock Price, News & Analysis

PureTech Health (Nasdaq: PRTC) announced the formation of a Clinical Advisory Board to advance LYT-100 (deupirfenidone) for idiopathic pulmonary fibrosis (IPF) and related lung diseases. The board consists of renowned experts in fibrosing lung diseases who will assist in the development of LYT-100, which aims to improve patient compliance due to its favorable safety profile compared to existing treatments. With around 200,000 patients affected by IPF in the U.S., this initiative addresses a significant medical need as current options have tolerability issues.

PureTech Health (Nasdaq: PRTC) announced new preclinical research published in Nature that suggests enhancing meningeal lymphatic drainage could significantly improve clinical outcomes for Alzheimer’s disease. The study links impaired lymphatic function to microglia activation issues, affecting treatment efficacy. This research potentially paves the way for new therapeutic approaches, working alongside existing immunotherapies targeting amyloid beta. PureTech holds an exclusive license for this intellectual property and is advancing this research within its meningeal lymphatics program.

PureTech Health plc (Nasdaq: PRTC) announced that its founded entity, Gelesis, appointed Jane Wildman to its Board of Directors. Wildman brings extensive experience from prominent companies and has a track record of success in brand growth. As Gelesis prepares for the U.S. launch of its weight management product, Plenity®, Wildman's marketing expertise is expected to significantly contribute to the company's strategies. Previously, she led Pampers at Procter & Gamble, doubling its sales from $4 billion to $8 billion. Gelesis focuses on innovative treatments for weight management and related health issues.

Vedanta Biosciences, a pioneering clinical-stage microbiome company, announces CEO Bernat Olle's participation in the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit on April 22, 2021. He will present on challenges and opportunities in microbiome-based therapeutics. A pre-recording of the presentations will be available at 8:00 AM ET on the same day. Vedanta focuses on developing oral therapies for immune-mediated diseases using defined bacterial consortia, overcoming limitations of donor-derived methods, with a robust clinical pipeline targeting conditions like C. difficile infection and inflammatory bowel diseases.

PureTech Health plc (Nasdaq: PRTC) announced its financial results for the year ending December 31, 2020, along with its cash balance as of March 31, 2021. The report highlights the company's commitment to developing innovative therapies for serious diseases. With a focus on clinical-stage biotherapeutics, PureTech aims to enhance patient outcomes through its advanced pharmaceutical solutions. The full financial details are accessible via the SEC's Form 20-F and on the company’s investor relations website.

PureTech Health (Nasdaq: PRTC) presented promising preclinical results for its LYT-210 antibody at the 2021 AACR Annual Virtual Meeting. The research shows LYT-210 is a highly specific and potent fully human monoclonal antibody targeting γδ1 T cells, which suppress the anti-tumor immune response. The in vitro studies demonstrate LYT-210's ability to induce cell death in these immune-suppressive cells while sparing vital T cells. This suggests potential for LYT-210 as a standalone treatment or in combination with other therapies, addressing several aggressive solid tumors and improving patient outcomes.

PureTech Health plc (Nasdaq: PRTC) has announced that its management team will present at two upcoming virtual investor conferences. The first is the 19th Annual Virtual Needham Healthcare Conference on April 12, 2021, featuring CFO George Farmer at 11:45 AM EDT. The second is a Fireside Chat with Liberum on April 28, 2021, with President Bharatt Chowrira and CFO George Farmer at 11:00 AM EDT. PureTech is focused on developing medicines for severe diseases and has a significant pipeline of 24 therapeutic candidates.

PureTech Health (Nasdaq: PRTC) announced that its Founded Entity, Akili Interactive, is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Vanderbilt University Medical Center to evaluate AKL-T01 as a treatment for cognitive dysfunction in COVID-19 survivors, commonly known as 'COVID brain fog'. The studies will investigate AKL-T01's effect on cognitive functioning through two randomized, controlled trials. With no current approved treatments for this condition, the studies aim to start recruitment next month, addressing a significant unmet medical need.

PureTech Health (Nasdaq: PRTC) notes the publication of data from the STARS Adjunct study by its Founded Entity, Akili Interactive, which evaluated the impact of EndeavorRx (AKL-T01) on ADHD symptoms in children. The study showed statistically significant improvements in all endpoints, marked by enhancements in daily life as rated by parents and clinicians. The results, published in Nature Digital Medicine, support previous FDA data leading to EndeavorRx's approval in June 2020, highlighting the potential of digital therapeutics in ADHD treatment.